UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Enfusion, Inc. (NYSE:ENFN – Free Report) by 43.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,721 shares of the company’s stock after purchasing an additional 10,173 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Enfusion were worth $347,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new position in Enfusion during the fourth quarter worth approximately $75,000. Millennium Management LLC purchased a new position in shares of Enfusion during the fourth quarter worth approximately $114,000. Dark Forest Capital Management LP acquired a new position in shares of Enfusion in the 4th quarter valued at $128,000. Man Group plc purchased a new stake in Enfusion in the 4th quarter valued at $131,000. Finally, Tower Research Capital LLC TRC boosted its stake in Enfusion by 58.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company’s stock worth $136,000 after purchasing an additional 4,889 shares during the period. 81.05% of the stock is owned by hedge funds and other institutional investors.
Enfusion Stock Performance
Shares of Enfusion stock opened at $10.85 on Friday. The company has a market capitalization of $1.40 billion, a P/E ratio of 271.29, a PEG ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a 1 year low of $7.83 and a 1 year high of $11.80. The company’s fifty day moving average is $10.83 and its two-hundred day moving average is $10.84.
Enfusion Profile
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Featured Articles
- Five stocks we like better than Enfusion
- What is a Death Cross in Stocks?
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- Stock Sentiment Analysis: How it Works
- 3 Stocks Set to Double—And There’s Still Time to Buy
- What is the NASDAQ Stock Exchange?
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.